Altimmune
ALT
2.59
-0.07
-2.63%
Altimmune
US · ALT
#3727 by market cap
2.59
-0.07
-2.63%
Live - 5344 symbols - heartbeat 428s ago
· 2026-10-08 10:00
Pre-market
2.66
0.00%
After-hours
2.67
+0.38%
Overnight
2.68
+0.75%
- Market cap
- 503.80M
- P/E (TTM)i
- -3.41
- P/Bi
- 1.06
- EPSi
- -1.00
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on ALT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.2 percentage points.
Institutional ownership
- Held by institutions
- 77.75% -1.23pp
- Institutions
- 241 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund36.49%
VC/PE Fund19.37%
Hedge Fund18.15%
Public Company2.31%
Private Company1.06%
Individual/Insider0.48%
Insurance Company0.23%
Government Pension Fund0.10%
Other21.78%
Top holders as of 2026-06-30
BlackRock
10.48% · 20.39M sh
Deep Track Capital, LP
9.90% · 19.25M sh
State Street Global Advisors
6.22% · 12.10M sh
TCG Crossover Management, LLC
5.14% · 10.00M sh
Vanguard Capital Management, LLC
4.87% · 9.47M sh
Vanguard Portfolio Management, LLC
3.77% · 7.33M sh
Marshall Wace LLP
3.52% · 6.84M sh
Viking Global Investors LP
3.44% · 6.70M sh
RA Capital Management, L.P.
3.34% · 6.50M sh
Geode Capital Management, LLC
2.58% · 5.01M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| Vipin Garg | Chief Executive Officer | 0.22% |
| M. Roberts | Chief Scientific Officer | 0.06% |
| Matthew Harris | Chief Medical Officer | 0.04% |
| Raymond Jordt | Chief Business Officer | 0.04% |
| Jerome Durso | Director | 0.03% |
| Gregory Weaver | Chief Financial Officer | 0.03% |
| Mitchel Sayare | Independent Chairperson | 0.01% |
| Christophe Arbet-Engels | Chief Medical Officer | 0.01% |
| John Gill | Independent Director | 0.01% |
| Linda Richardson | Chief Commercial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Gregory Weaver | Chief Financial Officer | Derivative Exercise and Sale | -4,379 | $2.76 |
| 2026-09-30 | Gregory Weaver | Chief Financial Officer | Derivative Exercise and Retained | +10,096 | -- |
| 2026-09-30 | Christophe Arbet-Engels | Chief Medical Officer | Derivative Exercise and Sale | -12,679 | $2.76 |
| 2026-09-30 | Christophe Arbet-Engels | Chief Medical Officer | Derivative Exercise and Retained | +24,821 | -- |
| 2026-09-15 | Linda Richardson | Chief Commercial Officer | Derivative Exercise and Sale | -6,826 | $3.24 |
| 2026-09-15 | Linda Richardson | Chief Commercial Officer | Derivative Exercise and Retained | +17,174 | -- |
| 2026-08-12 | Jerome Durso | Director | Open Market Acquisition | +15,000 | $2.95 |
| 2026-07-30 | Gregory Weaver | Chief Financial Officer | Other Acquisition | +1,753 | $2.41 |
| 2026-07-30 | M. Roberts | Chief Scientific Officer | Other Acquisition | +875 | $2.41 |
| 2026-04-30 | Mitchel Sayare | Independent Chairperson | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-30 | John Gill | Independent Director | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-30 | Philip Hodges | Independent Director | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-30 | Klaus Schafer | Independent Director | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-30 | Catherine Sohn | Independent Director | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-30 | Wayne Pisano | Independent Director | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-30 | Diane Jorkasky | Independent Director | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-30 | Teri Lawver | Director | Other Derivative Acquisition | +48,800 | $2.82 |
| 2026-04-05 | John Gill | Independent Director | Open Market Acquisition | +9,200 | $3.41 |
| 2026-03-31 | Gregory Weaver | Chief Financial Officer | Open Market Acquisition | +10,000 | $3.15 |
| 2026-03-31 | Jerome Durso | Director | Open Market Acquisition | +15,000 | $3.14 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:00:36 · For reference only, not investment advice and not tailored to your situation.